The global med-tech sector saw notable regulatory activity including FDA breakthrough designation granted to Cryofocus’ asthma cryoablation system. Meanwhile, policy shifts create a “pivotal moment” for life sciences companies as tariffs and pricing regulations impact long-term commercial strategies. A Deloitte survey reveals companies adapting via scenario planning and supply chain measures but slower to restructure operationally. In Europe, a €403 million investment package aims to stimulate medical device innovation incorporating digital and AI features. These combined forces are reshaping the operational environment for healthcare technology providers.